Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Towards personalized therapy for chronic GvHD

Nataliya Buxbaum • 24 Apr 2022
The 2022 Tandem Meetings
General

Nataliya Buxbaum, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, comments on the importance of personalizing treatment for chronic graft-versus-host disease (cGvHD). In the past five years, three drugs have been approved by the FDA for GvHD. However, it is still necessary to determine which drug is best for each patient. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Nataliya Buxbaum

0:45
St. Jude Children's Research Hospital & Roswell Park’s efforts to help pediatric patients in Ukraine
Nataliya Buxbaum • 24 Apr 2022
1:23
T-cell metabolism: a novel therapeutic avenue for GvHD
Nataliya Buxbaum • 24 Apr 2022

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals